Special articleRecommendations for Next-Generation Sequencing Germline Variant Confirmation: A Joint Report of the Association for Molecular Pathology and National Society of Genetic Counselors
Cited by (0)
Supported exclusively by the Association for Molecular Pathology.
Disclosures: To provide active management of potential perceived and/or actual conflicts of interest (COIs), a Working Group chair without relevant conflicts was appointed, and COI disclosures were requested from and/or provided by all authors throughout all phases of the consensus manuscript development process. K.D.F.H. is employed by Ambry Genetics (Aliso Viejo, CA). S.E.L. is employed by Invitae (Bethesda, MD). A.S. is employed by Veritas Genetics (Danvers, MA), a subsidiary of LetsGetChecked (PrivaPath Diagnostics, Dublin, Ireland); is cofounder of Opus Genomics (Durham, NC); and is equity holder in Opus Genomics, LetsGetChecked, and PathFinder Health (Seattle, WA).
The Next Generation Sequencing Germline Variant Confirmation Working Group of the Clinical Practice Committee, Association for Molecular Pathology (AMP), with organizational representation from the National Society of Genetic Counselors (K.D.F.H.). The AMP 2021 Clinical Practice Committee consisted of Jane Gibson (Chair), Fatimah Nahhas, Steven Sperber, Rashmi Goswami, Michael Kluk, Susan Hsiao, David Eberhard, Joseph Yao, Blake Buchan, Joshua Coleman, Elaine Gee, Andres Madrigal, and Jack Tung.
This article does not define standard of practice, and there may be alternatives. See Disclaimers for further details.